— Know what they know.
Not Investment Advice
Also trades as: ORNBV.HE (HEL) · $vol 17M · ORNAV.HE (HEL) · $vol 0M · ORINF (OTC) · $vol 0M

ORINY OTC

Orion Oyj
1W: +3.5% 1M: +6.6% 3M: +25.6% YTD: +32.4% 1Y: +31.4% 3Y: +171.5% 5Y: +161.6%
$48.79
+1.12 (+2.35%)
 
OTC · Healthcare · Drug Manufacturers - General · Tech Score Buy · Power 67 · $27.5B mcap · 246M float · 0.0001% daily turnover · Short 52% of daily vol
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$27.5B
52W Range30.89-48.7938
Volume5
Avg Volume157
Beta0.29
Dividend$0.99
Analyst Ratings
2 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOAino Anna Liisa Hurme
Employees4,029
SectorHealthcare
IndustryDrug Manufacturers - General
IPO Date2014-12-09
Orionintie 1A
Espoo, UU 02200
FI
358 10 4261
About Orion Oyj

Orion Oyj is a Finnish pharmaceutical company specializing in the creation, production, and commercialization of medicines for both human and animal health, as well as the active components (APIs) essential for drug formulation. Its operations extend across Finland, the Nordic region, wider Europe, North America, and various international markets. The company's diverse product portfolio encompasses both prescribed medications and over-the-counter (OTC) healthcare solutions. This includes notable offerings such as Nubeqa for prostate cancer therapy; Dexdor and Precedex, utilized as sedatives in intensive care settings; Stalevo and Comtess/Comtan addressing Parkinson's disease; Simdax for acute heart failure decompensation; and Fareston for breast cancer management. Additionally, a range of Easyhaler devices—like Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol—are provided for managing asthma and chronic obstructive pulmonary disease (COPD). Beyond human medicine, the firm supplies a suite of veterinary medications, including products such as Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. It also produces APIs for both proprietary and generic pharmaceutical products and offers specialized contract manufacturing capabilities. Furthermore, Orion Oyj distributes veterinary medicines manufactured by other global pharmaceutical entities. Its clientele spans a broad spectrum of healthcare stakeholders, from specialist and general physicians, veterinarians, and pharmacists to hospitals, healthcare centers, clinics, laboratories, and directly to consumers who own pets. Strategic alliances include a collaboration with Propeller Health aimed at integrating its Easyhaler® product range for asthma and COPD management with digital health solutions. Additionally, it holds a research collaboration and licensing deal with Alligator Bioscience AB (publ) focused on pioneering novel bispecific antibody-based cancer treatments. Established in 1917, Orion Oyj maintains its corporate headquarters in Espoo, Finland.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms